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Background
Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new anti-
tuberculosis medication that inhibits mycolic acid synthesis and has shown potent 
in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.
Methods
In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 
patients (nearly all of whom were negative for the human immunodeficiency virus) 
with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 
100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo 
(160 patients) for 2 months in combination with a background drug regimen devel-
oped according to World Health Organization guidelines. Sputum cultures were as-
sessed weekly with the use of both liquid broth and solid medium; sputum-culture 
conversion was defined as a series of five or more consecutive cultures that were 
negative for growth of M. tuberculosis. The primary efficacy end point was the propor-
tion of patients with sputum-culture conversion in liquid broth medium at 2 months.
Results
Among patients who received a background drug regimen plus 100 mg of delama-
nid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, 
as compared with 29.6% of patients who received a background drug regimen plus 
placebo (P = 0.008). Likewise, as compared with the placebo group, the group that 
received the background drug regimen plus 200 mg of delamanid twice daily had a 
higher proportion of patients with sputum-culture conversion (41.9%, P = 0.04). The 
findings were similar with assessment of sputum-culture conversion in solid medium. 
Most adverse events were mild to moderate in severity and were evenly distributed 
across groups. Although no clinical events due to QT prolongation on electrocardiog-
raphy were observed, QT prolongation was reported significantly more frequently 
in the groups that received delamanid.
Conclusions
Delamanid was associated with an increase in sputum-culture conversion at 2 months 
among patients with multidrug-resistant tuberculosis. This finding suggests that 
delamanid could enhance treatment options for multidrug-resistant tuberculo-
sis. (Funded by Otsuka Pharmaceutical Development and Commercialization; 
 ClinicalTrials.gov number, NCT00685360.)
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The emergence over the past two de-cades of multidrug-resistant tuberculosis, or tuberculosis caused by strains of Myco-
bacterium tuberculosis that are resistant to isoniazid 
and rifampin, with or without resistance to other 
agents, has greatly complicated efforts to control 
the global tuberculosis epidemic. Approximately 
440,000 cases of multidrug-resistant tubercu-
losis occur worldwide annually, accounting for 
nearly 5% of the global burden of tuberculosis.1 
Multidrug-resistant tuberculosis requires treat-
ment with combination therapy consisting of 
four to six medications, including the more toxic 
and less potent second-line drugs, administered 
for up to 2 years. Cure rates are lower and mor-
tality is higher with multidrug-resistant tubercu-
losis than with drug-susceptible tuberculosis, 
even with the most effective treatments.2-6 As a 
result, the Global Plan to Stop TB, 2011 through 
2015, calls for urgent development of new drugs 
involving new mechanisms to treat tuberculosis, 
including multidrug-resistant tuberculosis, as a 
key component of the response to the epidemic.7
Delamanid (OPC-67683), a new agent derived 
from the nitro-dihydro-imidazooxazole class of 
compounds that inhibits mycolic acid synthesis, 
has shown potent in vitro and in vivo activity 
against both drug-susceptible and drug-resistant 
strains of M. tuberculosis in preclinical develop-
ment.8,9 In a subsequent assessment of the 14-day 
early bactericidal activity of the compound against 
M. tuberculosis in patients in South Africa, dela-
manid administered at doses of 200 and 300 mg 
daily resulted in a decrease in the sputum M. tu-
berculosis burden that was similar to that of the 
potent antituberculosis drug rifampin in previ-
ous studies of early bactericidal activity.10,11
On the basis of results from five decades of 
controlled trials showing the predictive value of 
status with respect to sputum-culture conversion 
at 2 months for disease relapse among patients 
with tuberculosis, as well as cohort studies show-
ing its predictive value for treatment outcomes 
in multidrug-resistant tuberculosis, we conduct-
ed a multinational, randomized, double-blind, 
placebo-controlled trial to assess the safety, 
pharmacokinetic profile, and efficacy of dela-
manid in patients with multidrug-resistant tuber-
culosis.12-14 We present the results for patients 
with sputum culture–positive multidrug-resistant 
pulmonary tuberculosis who received 2 months 
of treatment with delamanid, at a higher or lower 
dose, or placebo in combination with a back-
ground drug regimen developed according to 
World Health Organization (WHO) guidelines.2
ME THODS
Patients
This study included patients 18 to 64 years of age 
who had sputum culture–positive multidrug-resis-
tant tuberculosis and chest radiographic find-
ings consistent with tuberculosis. Patients with 
sputum smears that were positive for acid-fast 
bacilli and positive rapid tests for rifampin resis-
tance were also enrolled, but they were excluded 
from the efficacy analysis if baseline cultures 
(i.e., results from cultures at day −1 and day 1) 
proved to be negative for multidrug-resistant tu-
berculosis. Patients were excluded from the trial 
if they had Karnofsky scores of less than 50%; 
those with human immunodeficiency virus (HIV) 
infection were excluded if they had a CD4 cell 
count of less than 350 per cubic millimeter or 
were receiving antiretroviral treatment. Patients 
who were receiving antiarrhythmic agents or who 
had clinically relevant cardiovascular disease or 
electrocardiographic (ECG) findings of conduc-
tion abnormalities or QT-interval prolongation 
(>450 msec in men or >470 msec in women) were 
also excluded, and the use of moxifloxacin was 
prohibited. Additional standard exclusion criteria 
were substance abuse, concomitant illness, drug 
hypersensitivity, abnormal renal and hepatic lab-
oratory results, pregnancy, and breast-feeding. 
Women with childbearing potential were required 
to use birth control.
Trial Design
This multicenter, double-blind, stratified, random-
ized, placebo-controlled trial was conducted in 
17 centers in nine countries: the Philippines, Peru, 
Latvia, Estonia, China, Japan, Korea, Egypt, and 
the United States. During the 8-week treatment 
period, all patients were hospitalized for intensive 
safety monitoring and weekly sputum-culture 
status assessments. The design included an ad-
ditional 4-week period of patient monitoring to 
confirm the sputum-culture status while patients 
continued to receive the background drug regi-
men. The objective of the trial was to evaluate the 
safety, efficacy, and pharmacokinetics of two dos-
es of delamanid (100 mg twice daily or 200 mg 
twice daily) plus the background drug regimen 
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for 2 months, as compared with placebo plus the 
standard drug regimen for 2 months.
Randomization was centralized, with patients 
stratified into two groups according to the ex-
tent of pulmonary tuberculosis (presence or ab-
sence of lung cavities) on baseline chest radiog-
raphy as assessed by local radiologists. Patients 
were randomly assigned in a 1:1:1 ratio to receive 
the background drug regimen plus delamanid at 
a dose of 100 mg or 200 mg or placebo twice 
daily for 8 weeks.
The study drug, provided as delamanid in 
50-mg tablets (Otsuka Pharmaceutical Develop-
ment and Commercialization) or matching place-
bo, was administered with morning and evening 
meals 10 hours apart, since systemic exposure 
increases when delamanid is taken with food; 
ingestion of all doses was observed. For 12 weeks, 
all patients received the background drug regi-
men developed according to WHO guidelines for 
treating multidrug-resistant tuberculosis; this 
regimen generally consisted of four or five anti-
tuberculosis medications, including any first-line 
medications to which a patient’s disease remained 
susceptible, an injectable antituberculosis medi-
cation (an aminoglycoside or capreomycin), a 
f luoroquinolone, and other medications.2 The 
background drug regimen could be adjusted by 
the site investigators as needed. After 8 weeks of 
blinded treatment, patients could continue the 
background drug regimen as outpatients and 
were assessed weekly for 4 additional weeks for 
sputum-culture status and safety findings.
The trial protocol, available with the full text 
of this article at NEJM.org, was approved by in-
dependent ethics committees and institutional 
review boards for all sites. All patients provided 
written informed consent in their native language 
before enrollment occurred. The trial was per-
formed in accordance with the Good Clinical 
Practice guidelines of the International Confer-
ence on Harmonization, adhered to the ethical 
principles of the Declaration of Helsinki, and was 
monitored by an independent data and safety 
monitoring committee. Otsuka sponsored the 
study, which was designed by employees of the 
sponsor with input from an academic author. 
Employees of the sponsor wrote the manuscript. 
All authors participated in the collection and 
analysis of the data and made the decision to 
submit the manuscript for publication. All au-
thors vouch for the completeness and accuracy 
of the data presented and the fidelity of the 
study to the protocol.
Study Procedures
Microbiologic Assessments
Morning sputum specimens were obtained dur-
ing the 8-week treatment period and during the 
4-week post-treatment period on days −1, 1, 8, 15, 
22, 29, 36, 43 50, 57, 63, 70, 77, and 84. If patients 
were unable to expectorate sputum, attempts were 
made to induce sputum expectoration with the 
use of aerosol inhalation. Sputum samples were 
deemed unobtainable if no sputum could be ob-
tained after induction. Samples were cultured in 
liquid broth medium (in an automated myco-
bacterial growth indicator tube [MGIT] system) 
(Becton Dickinson) and in solid mycobacterio-
logic culture medium (with the use of egg-based 
Löwenstein–Jensen medium for ≥90% of the pa-
tients). Mycobacterial cultures were identified 
according to the growth and morphologic char-
acteristics of the colony and with the use of com-
mercial identification methods, including DNA 
hybridization systems (e.g., Accuprobe), DNA 
amplification methods (e.g., INNO-LiPA Rif.TB 
[Innogenetics] and GenoType MTBDRplus [Hain 
Lifescience]), or other standardized methods. 
Microbiologic tests were performed in local labo-
ratories in accordance with guidelines from the 
Clinical and Laboratory Standards Institute for 
sputum processing, smear microscopy, culture 
techniques, drug-susceptibility testing, and iden-
tification of mycobacteria.15-17
On the basis of previous studies showing that 
in 18% of patients with multidrug-resistant tuber-
culosis who received the background drug regi-
men, the initial monthly cultures reverted from 
being negative to positive for M. tuberculosis,14 
sputum-culture conversion was defined as five or 
more consecutive weekly cultures that were nega-
tive for growth of M. tuberculosis (without subse-
quent positive cultures). The time of sputum-cul-
ture conversion was defined as the day of sputum 
collection for the first of five cultures that were 
negative for M. tuberculosis. Meeting this criterion 
required patients to have a negative culture by 
the end of the treatment period with the investi-
gational medication (day 57) and at all subsequent 
weekly assessments during the treatment period 
during which they received the background drug 
regimen alone (days 57, 63, 70, 77, and 84). In 
addition, since MGIT is automated, allowing for 
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standardization of processes across laboratories, 
and studies have shown that it is more sensitive 
than solid-culture media for detecting viable 
M. tuberculosis organisms,18 assessment of sputum-
culture conversion with the use of MGIT served as 
the primary efficacy analysis.
Pharmacokinetic Assessments
Serial blood samples were obtained over a 24-hour 
period on days 1, 14, 28, and 56. Plasma concen-
trations of delamanid were determined with the 
use of a validated liquid chromatography–mass 
spectrometry method at Tandem Labs, Salt Lake 
City. Summary tables were generated according 
to study-drug group for plasma concentrations 
per time point and for pharmacokinetic measures 
obtained with the use of WinNonlin software 
(Pharsight).
Safety Assessments
Safety tests included the following: monthly phys-
ical examinations, weekly assessment of vital 
signs, standard 12-lead ECG, clinical laboratory 
tests (including a hematologic profile, coagulation 
measurements, a urinalysis, and measurements 
of hepatic aminotransferase and thyroid and ad-
renal hormone levels), and baseline audiometry. 
The QT-interval duration for each ECG was 
 corrected with the use of Fridericia’s formula19: 
corrected QT interval = QT × (1000 ÷ RR interval in 
milliseconds)0.33. Use of concomitant medications 
was recorded daily, and adverse events were doc-
umented; immediately reportable events and 
clinically significant abnormal laboratory results 
were evaluated as appropriate.
Statistical Analysis
Safety evaluations were performed in all patients 
who underwent randomization and who received 
at least one dose of study medication (the inten-
tion-to-treat population). Efficacy evaluations were 
performed in all patients who had positive multi-
drug-resistant tuberculosis cultures at baseline 
and who met no exclusion criteria (the modified 
intention-to-treat population). The primary effi-
cacy end point was the proportion of patients in 
the modified intention-to-treat population who 
had sputum-culture conversion with the use of 
MGIT by 2 months (day 57) of treatment. Each of 
the delamanid groups was compared with the 
placebo group with the use of the Cochran–Mantel–
Haenszel test, stratified according to randomiza-
tion factor. The overall nominal significance level 
for testing the two pairwise comparisons was 
maintained at 0.05 (two-sided) with the use of 
the Hochberg multiple-testing procedure. Multi-
ple secondary efficacy end points were also as-
sessed, including sputum-culture conversion at 
2 months, with the use of solid medium and time 
to sputum-culture conversion with the use of both 
medium types in a proportional-hazards model. 
We analyzed the results of the sensitivity data sets 
of both the MGIT and solid-medium cultures with 
the use of the last-observation-carried-forward, 
observed-cases, and per-protocol methods; the 
analysis was not controlled for site. A single-
imputation method was used for any missing 
culture data. All end points were prespecified in 
a formal statistical analysis plan that was devel-
oped, finalized, and filed with regulatory author-
ities before database locking and unblinding. 
The Supplementary Appendix, including further 
details regarding study conduct and analyses, is 
available at NEJM.org.
R ESULT S
Study Population
Recruitment began in May 2008, and the last pa-
tient visit was in June 2010. A total of 611 patients 
with suspected multidrug-resistant tuberculosis 
were assessed for eligibility; 481 met eligibility 
requirements and were stratified into two groups 
according to the presence or absence of cavities 
observed in lung fields on chest radiography. 
Among the 481 patients in the intention-to-treat 
population, 402 (83.6%) met the criteria for the 
modified intention-to-treat population (positive 
sputum culture for multidrug-resistant tubercu-
losis at baseline) and were assessed for efficacy 
(141 patients who received delamanid at a dose of 
100 mg twice daily, 136 who received delamanid 
at a dose of 200 mg twice daily, and 125 who re-
ceived placebo) (Fig. 1). Of 402 patients who were 
assessed for efficacy, 217 were from Asia (54.0%), 
and 275 were men (68.4%); the median age was 
35 years (range, 18 to 63) (Table 1). No signifi-
cant differences in demographic or baseline clin-
ical characteristics between the intention-to-treat 
and modified intention-to-treat populations or 
among the three study-drug groups were identi-
fied. Although lung cavities were identified on 
chest radiography at baseline in equal proportions 
of patients across the groups, slightly fewer pa-
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tients in the placebo group than in the two dela-
manid groups had bilateral cavities. More than 
90% of patients had received treatment for tuber-
culosis before randomization; of these patients, 
more than 50% had received first-line antituber-
culosis drugs alone and nearly 40% had received 
a second-line or third-line antituberculosis drug. 
Details on the use of antituberculosis medication 
during the trial are included in the Supplemen-
tary Appendix. Four patients with HIV coinfec-
tion were enrolled, with at least one patient ran-
domly assigned to each group. Approximately 
85% of patients were fully adherent to the study-
drug regimen; only 1% of patients had adherence 
of 80% or less, and the proportion did not differ 
among the groups.
Safety
The safety analysis included the 481 patients in 
the intention-to-treat population (Fig. 1). Similar 
proportions of patients in the three study-drug 
groups completed the 8-week drug regimen 
(≥89%); a total of 14 patients (2.9%), evenly dis-
tributed across the groups, discontinued the study 
481 Underwent randomization
611 Patients were assessed for eligibility
130 Were excluded
91 Did not meet inclusion criteria
34 Declined to participate
5 Had other reasons
161 Were assigned to receive 100 mg
of delamanid twice daily
160 Were assigned to receive
placebo
18 (11.2%) Discontinued trial
13 (8.1%) Withdrew consent
4 (2.5%) Had adverse events
1 (0.6%) Met protocol withdrawal
criteria
15 (9.4%) Discontinued trial
5 (3.1%) Withdrew consent
4 (2.5%) Had adverse events
2 (1.3%) Met protocol withdrawal 
criteria
1 (0.6%) Was withdrawn by investi-
gator
1 (0.6%) Had protocol deviation
2 (1.3%) Were lost to follow-up
160 Were assigned to receive 200 mg
of delamanid twice daily
14 (8.8%) Discontinued trial
2 (1.3%) Withdrew consent
6 (3.8%) Had adverse events
4 (2.5%) Were withdrawn by
investigator
1 (0.6%) Had protocol deviation
1 (0.6%) Was lost to follow-up
161 Were included in the intention-
to-treat group and were assessed
for safety
141 (87.6%) Were included in the
modified intention-to-treat
group and assessed for efficacy
20  (12.4%) Were excluded from 
analysis owing to baseline 
culture status
17 (10.6%) Were not positive
for MTB
3 (1.9%) Were positive for MTB
and negative for MDR TB
160 Were included in the intention-to-
treat group and were assessed
for safety
125 (78.1%) Were included in the
modified intention-to-treat
group and assessed for efficacy
35  (21.9%) Were excluded from 
analysis owing to baseline 
culture status
19 (11.9%) Were not positive
for MTB
16 (10.0%) Were positive for
MTB and negative for 
MDR TB
160 Were included in the intention-
to-treat group and were assessed
for safety
136 (85.0%) Were included in the
modified intention-to-treat
group and assessed for efficacy
24  (15.0%) Were excluded from 
analysis owing to baseline 
culture status
18 (11.3%) Were not positive
for MTB
6 (3.8%) Were positive for MTB
and negative for MDR TB
Figure 1. Enrollment, Study-Drug Assignments, Follow-up, and Assessment of Patients.
MDR TB denotes multidrug-resistant tuberculosis, and MTB Mycobacterium tuberculosis.
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drug because of adverse events (see the Supple-
mentary Appendix for details).
Table 2 lists the adverse events that occurred 
in 10% or more of the patients in either or both 
of the delamanid groups and at a higher fre-
quency than that in the placebo group. There 
were fewer adverse events in the group of patients 
who received delamanid at a dose of 100 mg 
twice daily than in the group that received dela-
manid at a dose of 200 mg twice daily; many of 
these events were of similar frequency to those in 
the placebo group. No episodes of a prolonged 
QT interval as measured on ECG were associated 
with clinical manifestations such as syncope or 
arrhythmias. However, the frequency of a pro-
longed QT interval was higher in the group that 
received 200 mg of delamanid twice daily (13.1%) 
than in the group that received 100 mg twice 
daily (9.9%), and both rates were higher than that 
in the placebo group (3.8%). Concomitant condi-
tions that exacerbate QT-interval prolongation, 
particularly hypokalemia, which often result from 
the use of injectable antituberculosis medications, 
were noted.20 The percentage of patients with 
Table 1. Demographic and Baseline Clinical Characteristics of the Modified Intention-to-Treat Population 
for the Primary Efficacy Analysis.*
Characteristic
Delamanid, 100 mg 
Twice Daily
(N = 141)
Delamanid, 200 mg 
Twice Daily
(N = 136)
Placebo
(N = 125)
Total
(N = 402)
Age — yr
Median 36 33 35 35
Range 19–63 18–63 18–63 18–63
Male sex — no. (%) 91 (64.5) 95 (69.9) 89 (71.2) 275 (68.4)
Body-mass index†
Median 19.8 19.5 19.5 19.6
Range 12–31 12–40 12–31 12–40
Region — no. (%)‡
Americas 39 (27.7) 38 (27.9) 39 (31.2) 116 (28.9)
Southeast Asia 43 (30.5) 47 (34.6) 45 (36.0) 135 (33.6)
Northeast Asia 29 (20.6) 28 (20.6) 25 (20.0) 82 (20.4)
Eastern Europe or Mediterranean 30 (21.3) 23 (16.9) 16 (12.8) 69 (17.2)
Lung cavities — no. (%)
Absent 44 (31.2) 43 (31.6) 38 (30.4) 125 (31.1)
Unilateral 60 (42.6) 56 (41.2) 60 (48.0) 176 (43.8)
Bilateral 37 (26.2) 37 (27.2) 27 (21.6) 101 (25.1)
Previous treatment — no. (%)
<30 days before randomization 11 (7.8) 14 (10.3) 12 (9.6) 37 (9.2)
≥30 days before randomization 130 (92.2) 122 (89.7) 113 (90.4) 365 (90.8)
First-line only 72 (51.1) 73 (53.7) 68 (54.4) 213 (53.0)
Second-line with or without first-line 40 (28.4) 27 (19.9) 23 (18.4) 90 (22.4)
Third-line with or without first-line  
or second-line
18 (12.8) 22 (16.2) 22 (17.6) 62 (15.4)
* The modified intention-to-treat population included patients with confirmed sputum-culture–positive multidrug-resistant 
tuberculosis at trial baseline. Differences among the groups were not significant.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ The Americas region included Peru (98.3% of the patients) and the United States (1.7%). The Southeast Asia region 
consisted of the Philippines (100% of the patients). The Northeast Asia region included China (61.0% of the patients), 
Korea (29.2%), and Japan (9.8%). The Eastern Europe or Mediterranean region included Latvia (73.9% of the patients), 
Estonia (8.7%), and Egypt (17.4%).
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hepatotoxicity was not higher in the delamanid 
groups than in the placebo group. One patient 
died from tuberculosis during the trial. The Sup-
plementary Appendix provides a summary of ad-
verse events, including serious adverse events, 
discontinuation of the study drug due to adverse 
events, frequency of severe adverse events that 
developed during treatment, adverse events po-
tentially related to the study drug, and details of 
all adverse events (>400) that occurred in one or 
more patients.
Pharmacokinetics
Delamanid steady-state exposure increased less 
than proportionally with the dose. An increase in 
the dose of delamanid from 100 mg twice daily 
to 200 mg twice daily yielded a 50% increase in 
exposure. Plasma concentrations of delamanid 
decreased rapidly (half-life, 38 hours) after drug 
discontinuation. Pharmacokinetic measures (max-
imum concentration after morning and evening 
doses, minimum concentration, and area under 
the plasma concentration–time curve from 0 to 
Table 2. Incidence of Adverse Events (Occurring in ≥10% of Patients in Either Delamanid Group and with Greater 
Frequency Than in the Placebo Group).*
Adverse Event
Delamanid, 100 mg 
Twice Daily
(N = 161)
Delamanid, 200 mg 
Twice Daily
(N = 160)
Placebo
(N = 160)
number of patients (percent)
Hematopoietic
Anemia 18 (11.2) 10 (6.2) 14 (8.8)
Reticulocytosis 19 (11.8) 20 (12.5) 17 (10.6)
Gastrointestinal
Nausea 58 (36.0) 65 (40.6) 53 (33.1)
Vomiting 48 (29.8) 58 (36.2) 44 (27.5)
Upper abdominal pain 41 (25.5) 36 (22.5) 38 (23.8)
Cardiovascular
Palpitations 13 (8.1) 20 (12.5) 10 (6.2)
Prolonged QT interval on ECG 16 (9.9) 21 (13.1) 6 (3.8)
Respiratory: hemoptysis 19 (11.8) 15 (9.4) 17 (10.6)
Nervous system
Headache 36 (22.4) 41 (25.6) 30 (18.8)
Paresthesias 17 (10.6) 20 (12.5) 12 (7.5)
Tremor 19 (11.8) 16 (10.0) 13 (8.1)
Insomnia 42 (26.1) 51 (31.9) 42 (26.2)
General
Tinnitus 16 (9.9) 22 (13.8) 12 (7.5)
Asthenia 20 (12.4) 27 (16.9) 20 (12.5)
Malaise 12 (7.5) 16 (10.0) 12 (7.5)
Anorexia 23 (14.3) 34 (21.2) 24 (15.0)
Hyperhidrosis 9 (5.6) 17 (10.6) 8 (5.0)
Hyperuricemia 31 (19.3) 38 (23.8) 35 (21.9)
Hypokalemia 20 (12.4) 31 (19.4) 24 (15.0)
* With pairwise comparisons of the frequency of adverse events, only QT prolongation on electrocardiography (ECG) was 
significant (P = 0.048 for the comparison of the 100-mg group with the placebo group and P = 0.005 for the comparison 
of the 200-mg group with the placebo group). Furthermore, the Cochran–Armitage trend test used to evaluate for a dose–
response trend in the incidence of adverse events across the three dose groups (0 mg, 100 mg, and 200 mg twice daily) 
yielded a P value of 0.004 for QT prolongation detected by means of ECG.
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24 hours) for delamanid on day 56 are shown in 
the Supplementary Appendix.
Sputum-Culture Conversion
Of 481 patients who underwent randomization, 
402 (83.6%) had cultures that were positive for 
multidrug-resistant tuberculosis with the use of 
MGIT at baseline (the modified intention-to-treat 
population) and were included in the primary 
efficacy analysis. Of these 402 patients, the pro-
portion who had sputum-culture conversion with 
MGIT by 2 months in the group of patients who 
received delamanid at a dose of 100 mg twice 
daily was 45.4%, as compared with 29.6% in the 
placebo group (Fig. 2A); this was a significant 
increase (53%; 95% CI, 11 to 112; P = 0.008). The 
proportion who had sputum-culture conversion in 
the 200-mg group was similar (41.9%) and was 
significantly higher than that in the placebo group 
(P = 0.04). Results from the secondary analysis of 
sputum-culture conversion, assessed with the use 
of solid medium (Fig. 2B), as well as sensitivity 
analyses of the primary analysis, were consistent 
with the results of the primary analysis. These 
analyses included examination of data sets of 
sputum-culture conversion with the use of last-
observation-carried-forward, observed-cases, and 
per-protocol methods for both MGIT and solid 
medium, as well as evaluation of the data with 
the use of various less stringent definitions of 
sputum-culture conversion, including one routine-
ly used in clinical practice (two consecutive nega-
tive cultures obtained 1 month apart) and a single 
negative culture at 2 months. In addition, a multi-
ple-imputation strategy for dealing with missing 
sputum-culture results was used. In all cases, the 
proportion of patients with sputum-culture con-
version was higher in the groups receiving dela-
manid plus the background drug regimen, and 
in nearly all analyses, the difference was sig-
nificant.
An additional key secondary analysis assessed 
differences among the groups with respect to 
time to sputum-culture conversion. For this analy-
sis, Kaplan–Meier curves representing the time 
to conversion according to culture medium type 
(Fig. 3) showed 10% separation between the 
delamanid groups and the placebo group by day 
36 with MGIT. By the end of the 2-month treat-
ment period, the difference in sputum-culture 
conversion between the delamanid groups and 
the placebo group was significant (P = 0.001 for 
the comparisons of the 100-mg and 200-mg 
doses of delamanid with placebo); the same 
trend was observed with the use of solid medium 
(P = 0.0004 and P<0.0001, respectively, by the log-
rank test). In a Cox regression analysis of spu-
tum-culture conversion, including study-drug 
assignment and the presence or absence of cavi-
tation on chest radiography (a stratification vari-
able), the hazard ratio for increased time to con-
version to a negative sputum culture as assessed 
with the use of MGIT was 0.58 (95% confidence 
interval [CI], 0.39 to 0.89) in the 100-mg group 
and 0.63 (95% CI, 0.42 to 0.96) in the 200-mg 
group. The hazard ratio for increased time to con-
version to a negative sputum culture as assessed 
with the use of solid medium was 0.54 (95% CI, 
0.36 to 0.81) in the 100-mg group and 0.44 (95% 
CI, 0.29 to 0.64) in the 200-mg group.
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Figure 2. Proportion of Patients with Sputum-Culture Conversion by Day 57.
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Discussion
In this study, which used a stringent definition of 
sputum-culture conversion (five successive week-
ly cultures that were negative for M. tuberculosis) 
and a more sensitive culture system (MGIT) than 
solid medium for detecting viable M. tuberculo-
sis,18 45.4% of patients who received delamanid 
at a dose of 100 mg twice daily plus the back-
ground drug regimen had sputum-culture con-
version after 2 months, as compared with 29.6% 
of those who received placebo plus the back-
ground drug regimen; this was a significant in-
crease (53%; 95% CI, 11 to 112). This benefit, 
which was observed with both doses, was also 
observed with the use of solid-culture medium 
and was supported by sensitivity analyses and 
imputation strategies for missing sputum-cul-
ture results. Likewise, among patients who had 
sputum-culture conversion, those who received 
either delamanid dose plus the background drug 
regimen had sputum-culture conversion signifi-
cantly earlier than those who received placebo 
plus a background drug regimen.
The safety analyses showed that delamanid at 
either dose did not have dose-limiting toxicity; 
however, patients who received delamanid plus 
the background drug regimen had more epi-
sodes of QT-interval prolongation on scheduled 
ECG, as compared with those who received pla-
cebo plus the background drug regimen. None 
of these episodes were associated with clinical 
manifestations such as syncope or arrhythmias.
An analysis by Wallis and colleagues of mul-
tiple controlled clinical trials of tuberculosis treat-
ment involving 30 pairs of regimens and more 
than 5500 patients showed a strong association 
between increases in sputum-culture conversion 
at 2 months and lower tuberculosis relapse rates 
with the use of stepwise adjustments to treatment 
(e.g., adding a strong bactericidal agent to an 
existing regimen).12 Similarly, cohort studies have 
shown more favorable long-term treatment out-
comes among patients with multidrug-resistant 
tuberculosis who had sputum-culture conversion 
by 2 months as compared with those who did 
not.13,14 This trial shows that delamanid admin-
istered with the background drug regimen for 
multidrug-resistant tuberculosis enhanced and 
accelerated sputum-culture conversion. Long-term, 
open-label surveillance of patients with multi-
drug-resistant tuberculosis treated with delama-
nid and the background drug regimen is under 
way to extend efficacy and safety observations 
from this trial and to further document the du-
rability of response. Further analyses addressing 
pharmacology, long-term follow-up, and micro-
biologic data are also under way. A second large, 
randomized, controlled trial (ClinicalTrials.gov 
number, NCT01424670) of 6 months of treatment 
with delamanid as part of a full background 
drug regimen and including patients who have 
coinfection with HIV and multidrug-resistant 
tuberculosis and who are receiving antiretroviral 
drugs has been initiated and is designed to pro-
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Figure 3. Survival Analysis of Days to Sputum-Culture Conversion, According to 
Culture Medium Type.
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vide data on 30 months of follow-up of patients. 
It is important to learn more about the use of 
delamanid in combination with other new and 
existing antimycobacterial agents to develop better 
regimens for multidrug-resistant tuberculosis.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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mittee — Drs. Charles Daley, Thomas Fleming, Martin Keane, 
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